Michel Badin
Jersey City, NJNPI 1750305389
Payments from drug & device makers
Across 215 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$667
- E.r. Squibb & Sons, L.L.C.$438
- Merck$386
- Novartis$259
- Amgen$239
- Johnson & Johnson$190
- plus $1K from 35 others
What the payments were for
- Food & beverage$3,53898%
- Education$742%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $667 |
| E.r. Squibb & Sons, L.L.C. | 26 | $438 |
| Merck | 28 | $386 |
| Novartis | 16 | $259 |
| Amgen | 15 | $239 |
| Johnson & Johnson(2 entities) | 10 | $190 |
| Incyte Corporation | 9 | $131 |
| Bristol Myers Squibb | 9 | $119 |
| Pfizer | 8 | $117 |
| Bayer | 6 | $99 |
| Novo Nordisk | 6 | $93 |
| Jazz Pharmaceuticals Inc. | 4 | $63 |
| GSK | 4 | $57 |
| Astellas Pharma US Inc | 4 | $57 |
| Eisai Inc. | 4 | $56 |
| Lilly USA, LLC | 4 | $54 |
| Regeneron Healthcare Solutions, Inc. | 3 | $43 |
| Exelixis Inc. | 2 | $42 |
| Octapharma USA, Inc. | 2 | $40 |
| Gilead | 3 | $39 |
| Secura Bio, Inc. | 2 | $34 |
| Sanofi | 2 | $32 |
| AVEO Pharmaceuticals, Inc. | 2 | $31 |
| Ipsen Biopharmaceuticals, Inc | 1 | $31 |
| Boehringer Ingelheim | 2 | $30 |
| Global Blood Therapeutics, Inc. | 2 | $29 |
| Rigel Pharmaceuticals, Inc. | 2 | $26 |
| Novocure Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Blue Earth Diagnostics | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Adaptive Biotechnologies Corporation | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Myovant Sciences Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Sobi, Inc | 1 | $14 |
| EMD Serono, Inc. | 1 | $13 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $13 |
| Mylan Institutional Inc. | 1 | $12 |
| AbbVie | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 20 | $71,996 |
| Deferasirox | 14 | $2,925 |
| Zolpidem Tartrate | 15 | $91 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.